Assessing Naltrexone Prescribing and Barriers to Initiation for Alcohol Use Disorder: A Multidisciplinary, Multisite Survey.

Autor:	Leung JG; Pharmacy Services, Mayo Clinic, Rochester, MN, United States., Narayanan PP; Pharmacy Services, Mayo Clinic, Rochester, MN, United States., Markota M; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States., Miller NE; Mayo Family Clinic Kasson, Kasson, MN, United States., Philbrick KL; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States., Burton MC; Division of Hospital Internal Medicine, Mayo Clinic, Rochester, MN, United States., Kirchoff RW; Division of Hospital Internal Medicine, Mayo Clinic, Rochester, MN, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in psychiatry [Front Psychiatry] 2022 May 10; Vol. 13, pp. 856938. Date of Electronic Publication: 2022 May 10 (Print Publication: 2022).
DOI:	10.3389/fpsyt.2022.856938
Abstrakt:	Objective: To survey barriers in prescribing naltrexone for alcohol use disorder. Methods: A 12-question survey related to naltrexone prescribing patterns, perceptions, and knowledge was sent to 770 prescribers in the departments of internal medicine, family medicine, and psychiatry across a health system with sites in Arizona, Florida, and Minnesota. Results: Responses were obtained and included for 146/770 prescribers (19.0% response rate). Most respondents were in the department of internal medicine ( n = 94, 64.4%), but the departments of psychiatry ( n = 22, 15.1%) and family medicine ( n = 30, 20.5%) were also represented. Only 34 (23.3%) respondents indicated they had prescribed naltrexone in the previous 3 months. The most common reasons for not prescribing naltrexone were "unfamiliarity with naltrexone for treatment of alcohol use disorder" and "patients do not have appropriate follow-up or are not in a formal treatment program." Compared with those representing internal/family medicine, psychiatry respondents were more likely to prescribe naltrexone and answer knowledge questions correctly. Conclusion: In this survey among primarily non-addiction-trained prescribers, a disparity was shown for prescribing naltrexone and in knowledge barriers between staff in internal/family medicine and psychiatry. There exist opportunities for education and quality improvement that promote the prescribing of naltrexone for alcohol use disorder by non-addiction specialists. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Leung, Narayanan, Markota, Miller, Philbrick, Burton and Kirchoff.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu